Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized controlled trial (SEV COVID Trial)

Singh et al., medRxiv, doi:10.1101/2021.06.06.21258091
Jun 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 48% Improvement Relative Risk Mortality (b) 50% Recovery 14% Recovery (b) 8% HCQ  Singh et al.  LATE TREATMENT  RCT Is late treatment with HCQ + ribavirin beneficial for COVID-19? RCT 74 patients in India (March - October 2020) Lower mortality with HCQ + ribavirin (not stat. sig., p=0.45) c19hcq.org Singh et al., medRxiv, June 2021 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 417 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,800+ studies for 102 treatments. c19hcq.org
Very small early terminated RCT in India, showing lower mortality but without statistical significance with the very small sample size. Time since symptom onset is not provided. The recovery percentage for non-severe group B (86.7%) does not match any number of recoveries, we have used the closest number (15/17).
risk of death, 47.5% lower, RR 0.53, p = 0.45, treatment 3 of 20 (15.0%), control 6 of 21 (28.6%), NNT 7.4, severe.
risk of death, 50.0% lower, RR 0.50, p = 0.48, treatment 3 of 37 (8.1%), control 6 of 37 (16.2%), NNT 12, all patients.
risk of no recovery, 14.1% lower, RR 0.86, p = 0.76, treatment 9 of 20 (45.0%), control 11 of 21 (52.4%), NNT 14, severe.
risk of no recovery, 8.3% lower, RR 0.92, p = 1.00, treatment 11 of 37 (29.7%), control 12 of 37 (32.4%), NNT 37, all patients.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Singh et al., 8 Jun 2021, Randomized Controlled Trial, India, preprint, 13 authors, study period March 2020 - October 2020, this trial uses multiple treatments in the treatment arm (combined with ribavirin) - results of individual treatments may vary.
This PaperHCQAll
Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized controlled trial (SEV COVID Trial)
Budha O Singh, Bikram Moirangthem, Prasan Kumar Panda, Yogesh Arvind Bahurupi, Sarama Saha, Girraj Saini, Minakshi Dhar, Mukesh Bairwa, Venkatesh Srinivasa Pai, Ankit Agarwal, Girish Sindhwani, Shailendra Handu, Ravikant
doi:10.1101/2021.06.06.21258091
Background Definitive antiviral treatment is not available for COVID-19 infection except remdesivir that even with many doubts. Various combination antivirals have been tried. Methods A single-center, open-label, parallel-arm, stratified randomized controlled trial evaluated the therapeutic potential of hydroxychloroquine and lopinavir-ritonavir in combination with ribavirin in COVID-19. Enrolled patients in severe category were randomized into three groups: A: standard treatment, B: hydroxychloroquine+ribavirin+standard treatment, or C: lopinavir+ritonavir+ribavirin+standard treatment; while non-severe category into two groups: A: standard treatment or B: hydroxychloroquine+ribavirin. Combination antivirals was given for 10 days and followed for 28 days. The primary endpoints were safety, symptomatic and laboratory recovery of organ dysfunctions, and time to SARS-CoV-2 RT-PCR negative report. Results Total 111 patients randomized: 24, 23, and 24 in severe category A, B, and C respectively, and 20 in each non-severe group. Two patients receiving ribavirin experienced drug induced liver injury and another developed QT prolongation after hydroxychloroquine. In the severe category, 47.6%, 55%, and 30.09% in A, B, and C groups respectively showed symptomatic recovery compared to 93.3% and 86.7% in A and B groups respectively in the non-severe category at 72hrs (P>0.05). Conclusions The results failed to show statistical superiority of the antiviral combination therapies to that of the standard therapy in both the severe and non-severe categories in symptomatic adult patients of COVID-19. However, results do indicate the benefit of non-standard interventional combination therapy in severe disease. Furthermore, the dose of ribavirin needs to be reconsidered in the Indian population.
Given the results of the findings of the study and availability of a variety of therapeutic approaches including novel antivirals, modifiers of the immune response, or other intrinsic pathways, antiviral combinations may have a role in improving clinical recovery in patients of COVID-19 with severe category whereas only standard therapy is required for non-severe category. Competing interests: The authors declare that they have no competing interests. Trial registration: Funding: Non-funded. Authors' contributions: PKP conceived the trial. PKP, AB, BCS, GC, YAB designed the trial. BCS, BM, SS collected the data. All the authors are part of the trial management committee and were involved in the review, amendments, and approval of the final protocol.
References
Agarwal, Chen, Ravindran, To, Thuluvath, Gastrointestinal and Liver Manifestations of COVID-19, J Clin Exp Hepatol
Banerjee, Popoola, Shah, Ster, Quan et al., COVID-19 infection in kidney transplant recipients, Kidney Int
Bhatnagar, Murhekar, Soneja, Gupta, Giri et al., Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use, Indian J Med Res
Bikdeli, Madhavan, Jimenez, Chuich, Dreyfus et al., COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review, J Am Coll Cardiol
For, Control, Evidence used to update the list of underlying medical conditions that increase a person's risk of severe illness from COVID-19, US Dep Heal Hum Serv
Henry, De Oliveira, Benoit, Plebani, Lippi, Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis, Clin Chem Lab Med
Khalili, Zhu, Mak, Yan, Zhu, Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19, J Med Virol
Khalili, Zhu, Mak, Yan, Zhu, Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19, J Med Virol
Lippi, Wong, Henry, Hypertension in patients with coronavirus disease 2019 (COVID-19): A pooled analysis, Polish Arch Intern Med
Liu, Blet, Smyth, Li, The Science Underlying COVID-19: Implications for the Cardiovascular System, Circulation
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Pan, Peto, Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results, N Engl J Med, doi:10.1056/NEJMoa2023184
Sachdeva, Gianotti, Shah, Bradanini, Tosi et al., Cutaneous manifestations of COVID-19: Report of three cases and a review of literature, J Dermatol Sci
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review, JAMA -J Am Med Assoc
Schoergenhofer, Jilma, Stimpfl, Karolyi, Zoufaly, Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease, Annals of internal medicine
Sk, Roy, Jonniya, Poddar, Kar et al., Landscape analysis of COVID therapeutics as 21 March 2020, Pharmacological Research, doi:10.1016/j.scitotenv.2020.138277%0A10.1016/j.csbj.2020.03.025%0Ahttps://www.frontiersin.org/article/10.3389/fpubh
The, Food and Drug Administration FDA approves first treatment for COVID-19
Whittaker, Anson, Harky, Neurological Manifestations of COVID-19: A systematic review and current update, Acta Neurol Scand
Zambrano, Ellington, Strid, Galang, Oduyebo et al., Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States, MMWR Morb Mortal Wkly Rep
Zhou, Dai, Tong, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J Antimicrob Chemother
{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2024, 4, 24]], 'date-time': '2024-04-24T00:17:34Z', 'timestamp': 1713917854572}, 'posted': {'date-parts': [[2021, 6, 8]]}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'reference-count': 22, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2021, 6, 8]]}, 'abstract': '<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Definitive ' 'antiviral treatment is not available for COVID-19 infection except remdesivir that even with ' 'many doubts. Various combination antivirals have been ' 'tried.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A single-center, ' 'open-label, parallel-arm, stratified randomized controlled trial evaluated the therapeutic ' 'potential of hydroxychloroquine and lopinavir-ritonavir in combination with ribavirin in ' 'COVID-19. Enrolled patients in severe category were randomized into three groups: A: standard ' 'treatment, B: hydroxychloroquine+ribavirin+standard treatment, or C: ' 'lopinavir+ritonavir+ribavirin+standard treatment; while non-severe category into two groups: ' 'A: standard treatment or B: hydroxychloroquine+ribavirin. Combination antivirals was given ' 'for 10 days and followed for 28 days. The primary endpoints were safety, symptomatic and ' 'laboratory recovery of organ dysfunctions, and time to SARS-CoV-2 RT-PCR negative ' 'report.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Total 111 ' 'patients randomized: 24, 23, and 24 in severe category A, B, and C respectively, and 20 in ' 'each non-severe group. Two patients receiving ribavirin experienced drug induced liver injury ' 'and another developed QT prolongation after hydroxychloroquine. In the severe category, ' '47.6%, 55%, and 30.09% in A, B, and C groups respectively showed symptomatic recovery ' 'compared to 93.3% and 86.7% in A and B groups respectively in the non-severe category at ' '72hrs ' '(P&gt;0.05).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The ' 'results failed to show statistical superiority of the antiviral combination therapies to that ' 'of the standard therapy in both the severe and non-severe categories in symptomatic adult ' 'patients of COVID-19. However, results do indicate the benefit of non-standard interventional ' 'combination therapy in severe disease. Furthermore, the dose of ribavirin needs to be ' 'reconsidered in the Indian population.</jats:p></jats:sec>', 'DOI': '10.1101/2021.06.06.21258091', 'type': 'posted-content', 'created': {'date-parts': [[2021, 6, 8]], 'date-time': '2021-06-08T16:55:35Z', 'timestamp': 1623171335000}, 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized ' 'controlled trial (SEV COVID Trial)', 'prefix': '10.1101', 'author': [ {'name': 'SEV COVID trial group', 'sequence': 'first', 'affiliation': []}, {'given': 'Budha O', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bikram', 'family': 'Moirangthem', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-3008-7245', 'authenticated-orcid': False, 'given': 'Prasan Kumar', 'family': 'Panda', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yogesh Arvind', 'family': 'Bahurupi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sarama', 'family': 'Saha', 'sequence': 'additional', 'affiliation': []}, {'given': 'Girraj', 'family': 'Saini', 'sequence': 'additional', 'affiliation': []}, {'given': 'Minakshi', 'family': 'Dhar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mukesh', 'family': 'Bairwa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Venkatesh Srinivasa', 'family': 'Pai', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ankit', 'family': 'Agarwal', 'sequence': 'additional', 'affiliation': []}, {'given': 'Girish', 'family': 'Sindhwani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shailendra', 'family': 'Handu', 'sequence': 'additional', 'affiliation': []}, {'family': 'Ravikant', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2021061004300790000_2021.06.06.21258091v1.1', 'first-page': '1', 'volume': '2019', 'author': 'Centers for Disease Control and Prevention', 'year': '2020', 'journal-title': 'Evidence used to update the list of underlying medical conditions that ' 'increase a person’s risk of severe illness from COVID-19. US Dep Heal ' 'Hum Serv'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.kint.2020.03.018'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.3', 'doi-asserted-by': 'publisher', 'DOI': '10.15585/mmwr.mm6944e3'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.4', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/ane.13266'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.5', 'doi-asserted-by': 'publisher', 'DOI': '10.1515/cclm-2020-0369'}, { 'issue': '3', 'key': '2021061004300790000_2021.06.06.21258091v1.6', 'doi-asserted-by': 'crossref', 'first-page': '263', 'DOI': '10.1016/j.jceh.2020.03.001', 'article-title': 'Gastrointestinal and Liver Manifestations of COVID-19', 'volume': '10', 'year': '2020', 'journal-title': 'J Clin Exp Hepatol'}, { 'issue': '2', 'key': '2021061004300790000_2021.06.06.21258091v1.7', 'doi-asserted-by': 'crossref', 'first-page': '75', 'DOI': '10.1016/j.jdermsci.2020.04.011', 'article-title': 'Cutaneous manifestations of COVID-19: Report of three cases and a ' 'review of literature', 'volume': '98', 'year': '2020', 'journal-title': 'J Dermatol Sci'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.8', 'doi-asserted-by': 'publisher', 'DOI': '10.1161/CIRCULATIONAHA.120.047549'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.9', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0735-1097(20)33577-4'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.10', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41421-020-0156-0'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.11', 'unstructured': 'Indian Council of Medical Research [Internet]. Advisory on the use of ' 'Hydroxychloroquin as prophylaxis for SARS-CoV-2 infection [Internet]. ' '2020. p. 1–3. Available from: ' 'https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf'}, { 'issue': '7', 'key': '2021061004300790000_2021.06.06.21258091v1.12', 'doi-asserted-by': 'crossref', 'first-page': '1667', 'DOI': '10.1093/jac/dkaa114', 'article-title': 'COVID-19: a recommendation to examine the effect of hydroxychloroquine ' 'in preventing infection and progression', 'volume': '75', 'year': '2020', 'journal-title': 'J Antimicrob Chemother'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.13', 'doi-asserted-by': 'crossref', 'first-page': '670', 'DOI': '10.7326/M20-1550', 'article-title': 'Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized ' 'With Coronavirus Disease 2019 (COVID-19)', 'volume': '173', 'year': '2020', 'journal-title': 'Annals of internal medicine'}, { 'issue': '2 & 3', 'key': '2021061004300790000_2021.06.06.21258091v1.14', 'first-page': '184', 'article-title': 'Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus ' 'disease 2019 patients in India: Protocol for restricted public health ' 'emergency use', 'volume': '151', 'year': '2020', 'journal-title': 'Indian J Med Res'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.15', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.25798'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.16', 'first-page': '784', 'article-title': 'Landscape analysis of COVID therapeutics as 21 March 2020', 'volume': '18', 'year': '2020', 'journal-title': 'Pharmacological Research'}, { 'issue': '4', 'key': '2021061004300790000_2021.06.06.21258091v1.17', 'first-page': '304', 'article-title': 'Hypertension in patients with coronavirus disease 2019 (COVID-19): A ' 'pooled analysis', 'volume': '130', 'year': '2020', 'journal-title': 'Polish Arch Intern Med'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.18', 'unstructured': 'COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) ' 'Treatment Guidelines. National Institutes of Health. Available at ' 'https://www.covid19treatmentguidelines.nih.gov/.'}, { 'issue': '18', 'key': '2021061004300790000_2021.06.06.21258091v1.19', 'first-page': '1824', 'article-title': 'Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A ' 'Review', 'volume': '323', 'year': '2020', 'journal-title': 'JAMA - J Am Med Assoc'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.20', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.25798'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.21', 'unstructured': 'The U.S. Food and Drug Administration FDA approves first treatment for ' 'COVID-19. 2020. ' 'https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 ' 'accessed May 30th, 2021.'}, { 'key': '2021061004300790000_2021.06.06.21258091v1.22', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2023184'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2021.06.06.21258091', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 4, 23]], 'date-time': '2024-04-23T16:25:18Z', 'timestamp': 1713889518000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2021.06.06.21258091'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 6, 8]]}, 'references-count': 22, 'URL': 'http://dx.doi.org/10.1101/2021.06.06.21258091', 'relation': { 'is-preprint-of': [ { 'id-type': 'doi', 'id': '10.2147/cpaa.s325083', 'asserted-by': 'subject'}]}, 'subject': [], 'published': {'date-parts': [[2021, 6, 8]]}, 'subtype': 'preprint'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit